Kjelsåsveien 168 B
199 articles with Nordic Nanovector
Nordic Nanovector Presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting
Nordic Nanovector ASA announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector's chimeric anti-CD37 antibody coupled with the alpha-particle-generator lead-212, at the Society of Nuclear Medicine & Molecular Imaging 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June.
Nordic Nanovector to Present Preclinical Studies With 212Pb-NNV003, a Novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019
Nordic Nanovector ASA announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003 at the Targeted Radiopharmaceuticals Summit taking place in Munich, Germany on 12-13 June.
Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL
Nordic Nanovector ASA announces that the European Patent Organisation has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma.
Three of the board members of Nordic Nanovector ASA, Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total number of 11,840 RSUs that were issued to them in June 2018 after they had elected to receive all or part of their remuneration for the period from the annual general meeting in 2018 to the annual general meeting in 2019 in RSUs.
Nordic Nanovector to Present at Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference and ABGSC Oncology Seminar
Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during May and June:
The Board of Directors of Nordic Nanovector ASA has on 23 May 2019 resolved to grant 10,000 Performance Share Units to a new employee under the Company's equity incentive plan that was approved at the Company's annual general meeting held on 25 April 2019.
Nordic Nanovector ASA announces its results for the first quarter 2019.
Nordic Nanovector ASA announces that following a safety review of the first patients in the ongoing Archer-1 trial investigating Betalutin® in combination with rituximab in second-line follicular lymphoma, the Betalutin® dose has been escalated to 15 MBq/kg for the next cohort of patients.
Nordic Nanovector ASA announces that it will report its first quarter 2019 results on Thursday, 23 May 2019.
Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors - May 10, 2019
Reference is made to the minutes from Nordic Nanovector ASA's annual general meeting held on 25 April 2019 in Oslo, Norway.
Nordic Nanovector ASA announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance.
The Annual General Meeting of Nordic Nanovector ASA was held on 25 April 2019 in Oslo, Norway.
Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL
Nordic Nanovector ASA announces that the Safety Review Committee for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation has now reviewed safety data from the first three cohorts of patients.
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 25 April 2019 at 15.00 hours CEST at Thon Hotel Vika Atrium, Munkedamsveien 45 in Oslo.
Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11
Nordic Nanovector ASA notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy.
Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during April
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options - March 18, 2019
An individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 17,392 options through exercise of a corresponding number of free-standing warrants. 14,374 of the options are exercised at a strike price of NOK 30.00 per share, and 3,018 of the options are exercised at a strike price of NOK 14.24.
Reference is made to the stock exchange notice on 6 March 2019 where Nordic Nanovector ASA announced the final result of the repair offering, in which 69,051 shares, each with a nominal value of NOK 0.20, at a subscription price of NOK 45.00 were allocated.
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar
Nordic Nanovector ASA announces that members of its senior management team will participate and present at the following upcoming investor conferences during March